Treatment of Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Peripheral Neuropathy in Patients With Diabetes
Sponsor: Eli Lilly and Company
This PHASE3 trial investigates Diabetes Mellitus and Diabetic Neuropathies and is currently completed. Eli Lilly and Company leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jul 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarhus C, Denmark, Amersfoort, Netherlands, Atlanta, United States, Baltimore, United States, Bangalore, India, Boston, United States, Budapest, Hungary, Buffalo, United States, Burlington, United States, Camperdown, Australia and 60 more location s